Literature DB >> 2190624

Wegener's granulomatosis. Thoughts and observations of a pathologist.

F Wegener.   

Abstract

The clinical entity now known as Wegener's granulomatosis was first reported in 1936. Since then the disease's histopathology has been clarified, although its etiology remains unknown. Treatment requires immuno-suppressant therapy and careful following of affected patients. The present report reviews the historical background for the discovering of Wegener's granulomatosis and current clinical considerations.

Entities:  

Mesh：

Year:  1990        PMID： 2190624     DOI： 10.1007/bf00175962

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


  48 in total

1.  Wegener's granulomatosis: pathology and review of the literature.

Authors:  G C GODMAN; J CHURG
Journal:  AMA Arch Pathol       Date:  1954-12

2.  Wegener's granulomatosis.

Authors:  J L FAHEY; E LEONARD; J CHURG; G GODMAN
Journal:  Am J Med       Date:  1954-08       Impact factor: 4.965

Review 3.  [Therapy of Wegener's granulomatosis and related vasculitides].

Authors:  K Andrassy; J Koderisch; N Rasmussen; E Ritz
Journal:  Dtsch Med Wochenschr       Date:  1989-01-06       Impact factor: 0.628

4.  The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision?

Authors:  R A DeRemee
Journal:  Arthritis Rheum       Date:  1988-08

5.  Anti-neutrophil cytoplasmic autoantibodies.

Authors:  U Specks; M S Rohrbach; R A DeRemee
Journal:  N Engl J Med       Date:  1988-11-24       Impact factor: 91.245

6.  [Temporal follow-up of pulmonary Wegener's granulomatosis].

Authors:  H Hackl
Journal:  Pathologe       Date:  1987-09       Impact factor: 1.011

7.  Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis.

Authors:  G Lüdemann; W L Gross
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

8.  Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis.

Authors:  H L Israel
Journal:  Arch Intern Med       Date:  1988-10

9.  The eosinophilic variant of Wegener's granulomatosis.

Authors:  S A Yousem; C M Lombard
Journal:  Hum Pathol       Date:  1988-06       Impact factor: 3.466

10.  Wegener's granulomatosis.

Authors:  A D Kornblut; S M Wolff; H O deFries; A S Fauci
Journal:  Laryngoscope       Date:  1980-09       Impact factor: 3.325
View more
  5 in total

1.  Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.

Authors:  Achille Aouba; Christian Pagnoux; Boris Bienvenu; Alfred Mahr; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-12       Impact factor: 8.667

Review 2.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

3.  Historical perspective of vasculitis: polyarteritis nodosa and microscopic polyangiitis.

Authors:  Eric L Matteson
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

4.  Long-term damage to the ENT system in Wegener's granulomatosis.

Authors:  Marcos Martinez Del Pero; Michael Walsh; Raashid Luqmani; Oliver Flossmann; Chetan Mukhtyar; Piyush Jani; Niels Rasmussen; David Jayne
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-11-18       Impact factor: 2.503

Review 5.  The immunopathology of ANCA-associated vasculitis.

Authors:  Eoin F McKinney; Lisa C Willcocks; Verena Broecker; Kenneth G C Smith
Journal:  Semin Immunopathol       Date:  2014-07-24       Impact factor: 9.623
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.